Gedeon Richter Plc. confirmed that a new emergency contraceptive Plan B® One-Step (1.5 mg levonorgestrel 1x), developed and manufactured in finished dosage form by Gedeon Richter Plc. in partnership with Teva Pharmaceutical Industries Ltd., received final U.S. Food and Drug Administration approval.
Plan B® One-Step provides an innovative way of preventing unintended pregnancy with one tablet in one dose.
Teva has the exclusive rights to market and distribute the product in North-America.
Richter’s 1.5 mg levonorgestrel containing emergency contraceptive product has been already launched in several markets including Hungary, CIS republics and many of the European Union member states.
Gedeon Richter Plc. manufactures and markets a wide range of Women’s Healthcare products and is widely considered to be one of the leading companies in this therapeutic field. Richter has pioneered the development and introduction of emergency contraceptive products world-wide based on its focused strategy and expertise in steroid chemistry.
Plan B® One-Step is a registered trademark of Women’s Capital Corporation, a subsidiary of Duramed Pharmaceuticals, Inc.
Posts
No comments:
Post a Comment